Dexcom (NSDQ:DXCM) topped expectations on Wall Street this week with its fourth quarter and full-year financial results.
The San Diego, Calif.-based company posted a net loss of -$179.7 million, or -$2.03 per share, on sales of $338 million for the 3 months ended Dec. 31, for sales growth of 52.9% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Dexcom beats The Street with Q4, FY18 results appeared first on MassDevice.
from MassDevice https://ift.tt/2Sl5cO6
Cap comentari:
Publica un comentari a l'entrada